Platelet Reactivity: Is There a Role to Switch?

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Antiplatelet agents are crucial for preventing thrombotic events in coronary artery disease, particularly after acute coronary syndrome or percutaneous coronary intervention (PCI).
• Balancing the benefits of preventing thrombosis against the risk of bleeding is essential for effective antiplatelet strategies.
• Platelet function testing was proposed to personalize antiplatelet therapy and optimize the benefit/risk ratio.

Purpose of the Study:

• To review available trial and registry data on the role of platelet reactivity testing in guiding antiplatelet treatment selection for patients undergoing PCI.
• To discuss the limitations and shortcomings of studies evaluating platelet function testing in this context.

Main Methods:

• Systematic review of randomized trials and clinical registries.
• Analysis of studies investigating the impact of platelet function testing on clinical outcomes in patients undergoing PCI.

Main Results:

• Randomized trials have consistently failed to demonstrate improved clinical outcomes with treatment selection guided by platelet function testing.
• Platelet function testing has not become a routine component in managing antiplatelet therapies due to lack of proven clinical benefit.

Conclusions:

• Despite the theoretical appeal, current evidence does not support the routine use of platelet function testing to guide antiplatelet therapy in patients undergoing PCI.
• Further research may be needed to clarify the precise role, if any, of platelet reactivity testing in optimizing antiplatelet strategies.